II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: Evaluation of plasmid DNA persistence and integration potential

Human Gene Therapy

Volumn 16, Issue 10, 2005, Pages 1151-1156

  Vilalta, Adrián ^a,b   Mahajan, Rohit K ^a   Hartikka, Jukka ^a   Leamy, Vicky ^a   Martin, Terrie ^a   Rusalov, Denis ^a   Bozoukova, Vesselina ^a   Lalor, Peggy ^a   Hall, Keith ^a   Kaslow, David C ^a   Rolland, Alain ^a  

^a Vical   (United States)

^b VICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYLGLYCERO 3 PHOSPHOETHANOLAMINE; ANTHRAX VACCINE; CATION; DNA VACCINE; LIPID; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACILLUS ANTHRACIS; DRUG FORMULATION; GEL ELECTROPHORESIS; GENE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; REAL TIME POLYMERASE CHAIN REACTION; RECTUS FEMORIS MUSCLE; SKELETAL MUSCLE; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; DRUG EVALUATION, PRECLINICAL; HUMANS; INJECTIONS, INTRAMUSCULAR; LIPIDS; MUSCLE, SKELETAL; PHOSPHATIDYLETHANOLAMINES; PLASMIDS; QUATERNARY AMMONIUM COMPOUNDS; RABBITS; VACCINES, DNA;

BACILLUS ANTHRACIS; ORYCTOLAGUS CUNICULUS;

EID: 26644468124     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1151     Document Type: Article

References (20)

1. COLE, J., and SKOPEK, T.R. (1994). International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 3. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. Mutat. Res. 304, 33-105.
2. DAVIS, B.S., CHANG, G.J., CROPP, B., ROEHRIG, J.T., MARTIN, D.A., MITCHELL, C.J., BOWEN, R., and BUNNING, M.L. (2001). West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75, 4040-4047.
3. FISCHER, L., MINKE, J., DUFAY, N., BAUDU, P., and AUDONNET, J.C. (2003). Rabies DNA vaccine in the horse: Strategies to improve serological responses. Vaccine 21, 4593-4596.
4. GALANIS, E. (2002). Technology evaluation: Allovectin-7, Vical. Curr. Opin. Mol. Ther. 4, 80-87.
5. GALLOWAY, D., LINER, A., LEGUTKI, J., MATECZUN, A., BARNEWALL, R., and ESTEP, J. (2004). Genetic immunization against anthrax. Vaccine 22, 1604-1608.
6. HARTIKKA, J., BOZOUKOVA, V., FERRARI, M., SUKHU, L., ENAS, J., SAWDEY, M., WLOCH, M.K., TONSKY, K., NORMAN, J., MANTHORPE, M., and WHEELER, C.J. (2001). Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19, 1911-1923.
7. HERMANSON, G., WHITLOW, V., PARKER, S., TONSKY, K., RUSALOV, D., FERRARI, M., LALOR, P., KOMAI, M., BELL, M., BRENNEMAN, K., MATECZUN, A., EVANS, T., KASLOW, D., GALLOWAY, D.R., and HOBART, P. (2004). A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl. Acad. Sci. U.S.A. 101, 13601-13606.
8. ILAR (INSTITUTE OF LABORATORY ANIMAL RESEARCH), COMMISSION ON LIFE SCIENCES, NATIONAL RESEARCH COUNCIL. (1996). Guide for the Care and Use of Laboratory Animals. (National Academies Press, Washington, D.C.).
9. KANG, K.K., CHOI, S.M., CHOI, J.H., LEE, D.S., KIM, C.Y., AHN, B.O., KIM, B.M., and KIM, W.B. (2003). Safety evaluation of GX-12, a new HIV therapeutic vaccine: Investigation of integration into the host genome and expression in the reproductive organs. Intervirology 46, 270-276.
10. KAUSHIK, A. (2001). Leuvectin: Vical Inc. Curr. Opin. Investig. Drugs 2, 976-981.
11. LEDWITH, B.J., MANAM, S., TROILO, P.J., BARNUM, A.B., PAULEY, C.J., GRIFFITHS, T.G., II, HARPER, L.B., BEARE, C.M., BAGDON, W.J., and NICHOLS, W.W. (2000a). Plasmid DNA vaccines: Investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43, 258-272.
12. LEDWITH, B.J., MANAM, S., TROILO, P.J., BARNUM, A.B., PAULEY, C.J., GRIFFITHS, T.G., II, HARPER, L.B., SCHOCK, H.B., ZHANG, H., PARIS, J.E., WAY, P.A., BEARE, C.M., BAGDON, W.J., and NICHOLS, W.W. (2000b). Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev. Biol. (Basel) 104, 33-43.
13. MARTIN, T., PARKER, S.E., HEDSTROM, R., LE, T., HOFFMAN, S.L., NORMAN, J., HOBART, P., and LEW, D. (1999). Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection. Hum. Gene Ther. 10, 759-768.
14. NICHOLS, W.W., LEDWITH, B.J., MANAM, S.V., and TROILO, P.J. (1995). Potential DNA vaccine integration into host cell genome. Ann. N.Y. Acad. Sci. 772, 30-39.
15. NORMAN, J., HARTIKKA, J., STRAUCH, P., and MANTHORPE, M. (1999). Adjuvants for plasmid DNA vaccines. Methods Mol. Med. 29, 185-196.
16. REUVENY, S., WHITE, M.D., ADAR, Y.Y., KAFRI, Y., ALTBOUM, Z., GOZES, Y., KOBILER, D., SHAFFERMAN, A., and VELAN, B. (2001). Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69, 2888-2893.
17. SAN, H., YANG, Z.Y., POMPILI, V.J., JAFFE, M.L., PLAUTZ, G.E., XU, L., FELGNER, J.H., WHEELER, C.J., FELGNER, P.L., GAO, X., HUANG, L., GORDON, D., NABEL, G.J., and NABEL, E.G. (1993). Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum. Gene Ther. 4, 781-788.
18. SULLIVAN, N.J., SANCHEZ, A., ROLLIN, P.E., YANG, Z.Y., and NABEL, G.J. (2000). Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609.
19. VILALTA, A., MAHAJAN, R., HARTIKKA, J., RUSALOV, D., MARTIN, T., BOZOUKOVA, V., LEAMY, V., HALL, K., LALOR, P., ROLLAND, A., and KASLOW, D. (2005). I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: Evaluation of plasmid DNA biodistribution/persistence and integration. Hum. Gene Ther. 16, 1143-1150.
20. WOLFF, J.A., LUDTKE, J.J., ACSADI, G., WILLIAMS, P., and JANI, A. (1992). Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Genet. 1, 363-369.